Parmax Pharma Limited has announced the appointment of Ms. Bhakti Aghera as Company Secretary and Compliance Officer, marking a key addition to the company's management team. The appointment was formalized through a regulatory filing with BSE Limited on March 25, 2026.

Board Approval and Regulatory Compliance

The Board of Directors approved Ms. Aghera's appointment during their meeting held on March 25, 2026, acting on the recommendation of the Nomination and Remuneration Committee. The appointment is effective from March 25, 2026, and has been communicated to BSE Limited in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

Professional Background

Ms. Bhakti Aghera brings substantial expertise to her new role as an associate member of The Institute of Company Secretaries of India. She possesses six years of knowledge and experience in corporate legal and secretarial services. Notably, she has previously worked with Parmax Pharma Limited, providing her with valuable familiarity with the company's operations and regulatory requirements.

Regulatory Framework

The appointment follows the prescribed regulatory framework under Regulation 30 read with Para A(7) of Part A of Schedule III of the Listing Regulations. The company has also complied with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring all required disclosures for changes in Key Managerial Personnel are properly documented and communicated to the stock exchange.

Parmax Pharma Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, revealing continued operational challenges with widening losses and declining revenue performance. The Board of Directors approved these results during their meeting held on February 14, 2026.

Q3 FY26 Financial Performance

The pharmaceutical company reported deteriorating financial metrics for the third quarter of FY26. The company's operational revenue and profitability showed significant decline compared to the corresponding quarter of the previous year.

The company's basic earnings per share deteriorated to -1.96 for Q3 FY26 compared to -1.05 in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

The nine-month period ending December 31, 2025, showed even more concerning trends with substantial losses accumulating over the period.

Expense Structure and Cost Management

The company's expense breakdown for Q3 FY26 revealed significant cost components affecting profitability:

Notably, the company reported a positive change in inventories of Rs 2.85 lakh, indicating inventory reduction during the quarter.

Corporate Governance and Board Meeting Outcome

The Board of Directors, led by Managing Director Umang Alkesh Gosalia, approved these results during their meeting held on February 14, 2026. The meeting commenced at 16:30 PM IST and concluded at 17:50 PM IST. The results have been reviewed by the Audit Committee and audited by statutory auditors, who issued an unqualified audit report.

The company submitted these unaudited standalone financial results under Regulation 33 of SEBI (LODR) Regulations, 2015, ensuring compliance with statutory requirements. The results were prepared in accordance with the prescribed format under Schedule III of Companies Act, 2013.

Operational Notes and Insurance Claims

The company operates exclusively in the pharmaceutical segment and has lodged an insurance claim with the insurance company, where the surveyor provided an insurance provision amounting to Rs 3.50 crore. Additionally, during the nine months ended December 31, 2025, the company did not charge depreciation on the clean room plant and effluent treatment plant.

Parmax Pharma Limited maintains a paid-up equity share capital of Rs 3,74,13,000, consisting of shares with a face value of Rs 10.00 each. The share capital structure remained unchanged throughout the reporting periods, providing stability in the company's capital base despite operational challenges.